about
Application of PK/PD Modeling in Veterinary Field: Dose Optimization and Drug Resistance PredictionPharmacokinetic and pharmacodynamic considerations in antimalarial dose optimizationInterplay in the selection of fluoroquinolone resistance and bacterial fitnessEvaluation of meropenem regimens suppressing emergence of resistance in Acinetobacter baumannii with human simulated exposure in an in vitro intravenous-infusion hollow-fiber infection model.Mutant prevention concentration-based pharmacokinetic/pharmacodynamic indices as dosing targets for suppressing the enrichment of levofloxacin-resistant subpopulations of Staphylococcus aureusTigecycline-Amikacin Combination Effectively Suppresses the Selection of Resistance in Clinical Isolates of KPC-Producing Klebsiella pneumoniae.CD101: a novel long-acting echinocandin.Quinolones: action and resistance updated.Emergence and spread of antibiotic resistance following exposure to antibiotics.Epidemiology, treatment and prevention of healthcare-associated urinary tract infections.Dosing regimen matters: the importance of early intervention and rapid attainment of the pharmacokinetic/pharmacodynamic target.Unraveling Drug Penetration of Echinocandin Antifungals at the Site of Infection in an Intra-Abdominal Abscess Model.Pharmacokinetic/pharmacodynamic evaluation of marbofloxacin as a single injection for Pasteurellaceae respiratory infections in cattle using population pharmacokinetics and Monte Carlo simulations.Revisiting the mutant prevention concentration to guide dosing in childhood tuberculosis.Mutant prevention concentration of tigecycline for clinical isolates of Streptococcus pneumoniae and Staphylococcus aureus.Minimal inhibitory and mutant prevention concentrations of azithromycin, clarithromycin and erythromycin for clinical isolates of Streptococcus pneumoniae.Effect of ciprofloxacin concentration on the frequency and nature of resistant mutants selected from Pseudomonas aeruginosa mutS and mutT hypermutators.Influence of inoculum size and marbofloxacin plasma exposure on the amplification of resistant subpopulations of Klebsiella pneumoniae in a rat lung infection model.In vitro effect of qnrA1, qnrB1, and qnrS1 genes on fluoroquinolone activity against isogenic Escherichia coli isolates with mutations in gyrA and parC.Time-kill kinetics of anti-tuberculosis drugs, and emergence of resistance, in relation to metabolic activity of Mycobacterium tuberculosis.Rates and mechanisms of resistance development in Mycobacterium tuberculosis to a novel diarylquinoline ATP synthase inhibitor.Testing the mutant selection window hypothesis with Escherichia coli exposed to levofloxacin in a rabbit tissue cage infection model.Exploring the role of the immune response in preventing antibiotic resistance.The path of least resistance: aggressive or moderate treatment?Characteristics of the antibiotic regimen that affect antimicrobial resistance in urinary pathogens.
P2860
Q26753831-4BDFB30D-F68A-487B-8CD8-3DD91EC74ED2Q26830528-C818E166-2675-44E9-99D1-38167EE8C874Q28475870-78BB6E1F-8B5C-4F70-82CC-9062AD66CB3EQ34596344-71E12554-4760-4E0B-AA31-7D4BFFFB57E1Q34932274-84B71BDA-D0F8-4B6D-B3D6-C31873A08551Q37188061-D8E0200C-50D2-40DD-9589-34F28E5958D7Q37394523-90995028-0F82-4E08-9CC0-6F8571238753Q37595559-7DEF1126-EE03-478F-B80E-03CF31DD479CQ37896674-9A7A3CDD-8A96-4C34-B5B2-F43968A75FB4Q37928501-797633D3-01F7-419D-9CF1-8E234C886945Q37988861-BB08435A-7068-4F97-A7FD-813CF3D15DE6Q40121744-9385C41F-FB2C-4195-8BDD-46B35AABFE53Q40199060-B9B63956-BA09-4EAD-8706-D18E37E611BDQ40282057-010C0F3F-E8CF-4021-91E6-097087065FDCQ41697443-9FC4A1EB-458F-4107-90FD-D4D8D72F8EC0Q41785898-705E2880-CB43-4255-BCE7-CA63F8027E70Q41833848-1E77ADD9-85BC-47C5-8020-A94D996C5459Q42612081-62C506E9-6841-4491-BE17-FFECCFC6A1DFQ42706278-08668DCB-810A-41ED-B392-C01DF677639FQ42858670-F88D1DCA-2234-41D0-9811-9AF906D38923Q42910136-AF617DF8-6189-4CDF-97CC-4C22607F764EQ43988363-12EB9B9B-3ED2-4003-A3F2-1EE5CC556CAEQ44028719-369AF299-3800-470E-BDE8-9964757485D1Q51033406-6E893FAF-739E-451E-9305-D9D05D17BD9AQ55425413-39275F2D-9C1E-4F66-A48B-B7D9D49B30DF
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 June 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A unified anti-mutant dosing strategy.
@en
A unified anti-mutant dosing strategy.
@nl
type
label
A unified anti-mutant dosing strategy.
@en
A unified anti-mutant dosing strategy.
@nl
prefLabel
A unified anti-mutant dosing strategy.
@en
A unified anti-mutant dosing strategy.
@nl
P2860
P356
P1476
A unified anti-mutant dosing strategy.
@en
P2093
Karl Drlica
Xilin Zhao
P2860
P304
P356
10.1093/JAC/DKN229
P407
P577
2008-06-10T00:00:00Z